UniQure halves re­search, lays off 20% while CSO de­parts in ma­jor re­vamp

Last year
People
R&D

BMS-backed liq­uid biop­sy biotech Pre­cede Bio­sciences de­buts to en­hance pre­ci­sion med­i­cine ap­proach­es

Last year
Financing
Startups

Health tech start­up At­ro­pos re­veals gen­er­a­tive AI tool for pars­ing pa­tient records

Last year
Health Tech

FDA hands down par­tial clin­i­cal hold to In­nate Phar­ma for can­cer drug tri­als af­ter pa­tient death

Last year
FDA+

Gene ther­a­py mak­er Or­chard Ther­a­peu­tics sells to Ky­owa Kirin for $387M cash as lead pro­gram awaits 2024 FDA ver­dict

Last year
Deals
Cell/Gene Tx

EQRx had lim­it­ed buy­er in­ter­est, tried ac­quir­ing oth­er com­pa­nies be­fore Rev­o­lu­tion came for its cash

Last year
Deals

FDA's on­col­o­gy ad­vi­so­ry com­mit­tee backs po­ten­tial high-risk neu­rob­las­toma treat­ment

Last year
FDA+

Patent ap­peal board takes up Ozem­pic chal­lenge

Last year
Pharma

Slew of phar­ma in­dus­try play­ers form coali­tion to push back against an­titrust re­form

Last year
Pharma
FDA+

San­doz shares dip on first day of Swiss list­ing af­ter No­var­tis spin­off

Last year
Pharma

So­ma­Log­ic, Stan­dard BioTools to merge in­to $1B mul­ti-omics tech provider

Last year
Deals
Manufacturing

Free­line’s ear­ly Gauch­er dis­ease da­ta; Shorla rais­es $35M; Re­genxbio to start piv­otal DMD tri­al next year

Last year
News Briefing

A con­ver­sa­tion with No­bel Prize win­ner Katal­in Karikó on re­jec­tion, fi­nal­ly be­ing rec­og­nized and her mR­NA work

Last year
People

New York Blood Cen­ter En­ter­pris­es buys Ta­laris’ cell ther­a­py fa­cil­i­ties in CD­MO ex­pan­sion

Last year
Manufacturing

Lil­ly's di­a­betes and obe­si­ty leader to re­tire in broad­er lead­er­ship shuf­fle as CSO Dan Skovron­sky takes on im­munol­o­gy ...

Last year
People
Pharma

Kezar changes CEOs, lays off 41% of staff and halts pre­clin­i­cal R&D to ex­tend cash run­way

Last year
People
R&D

Mod­er­na eyes PhI­II start for com­bo mR­NA jab tar­get­ing Covid and flu af­ter PhI/II suc­cess

Last year
R&D
Coronavirus

GLP-1 gene ther­a­py trig­gers 25% weight loss in obese mice, clin­i­cal tri­als planned for next year

Last year
R&D
Cell/Gene Tx

Up­dat­ed: Sanofi's $1.5B pact with Te­va in IBD adds fu­el to an­ti-TL1A race against Mer­ck, Roivant and Pfiz­er

Last year
Deals

Ver­tex says an­oth­er type 1 di­a­betes pa­tient is in­sulin-free in up­dat­ed da­ta out of EASD

Last year
R&D

Clin­i­cal ef­fi­ca­cy stud­ies should not be the de­fault for biosim­i­lars de­vel­op­ment, FDA says

Last year
FDA+

We­govy, Ozem­pic ex­clu­siv­i­ty chal­lenges de­nied by US patent ap­peal board

Last year
Pharma

FDA clears No­vavax’s fall boost­er for Covid-19, weeks af­ter mR­NA vac­cine boost­ers 

Last year
Pharma
FDA+

FDA of­fers pos­i­tive sig­nals for po­ten­tial pe­di­atric neu­rob­las­toma drug ahead of ODAC meet­ing

Last year
FDA+
First page Previous page 269270271272273274275 Next page Last page
A service from the Financial Times